Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Strides Shasun Ltd    STAR   INE939A01011

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Strides Arcolab Limited : Strides Arcolab Receives US FDA Nod To Commercialize First Liquid Injectable Product From Its New Facility

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/11/2012 | 03:03am CEST

Press Release
Wednesday, April 13, 2011

Strides Arcolab Limited, Strides House, Bannerghatta Road, Bangalore - 560076, India

BSE: 532531

NSE: STAR

STRIDES ARCOLAB RECEIVES US FDA NOD TO COMMERCIALIZE

FIRST LIQUID INJECTABLE PRODUCT FROM ITS NEW FACILITY

• First shipments to commence in April 2011

April 13, 2011, Bangalore: Strides Arcolab Limited (Strides) today announced that it has received approval from the US FDA to commercialize the first liquid injection sterile product from the Company's new Sterile Injectable complex in Bangalore. The approved product has been facing prolonged shortage in the USA and approval from the new facility will offer Strides unconstrained capacities to meet the market demand.

With this approval, significant capacity will be released from the existing site enabling

Strides to commercialize additional liquid injectable products.

Strides had earlier announced approval for Vancomycin Injection from its new facility in Bangalore in a lyophilized format and the Company has already started supplies to the US market in March 2011.

Commenting on this development Venkat Iyer, CEO, Agila Specialties, said, "The US FDA approval for the product from the new site will go a long way in ameliorating product shortages in critical therapeutic areas. Two significant product approvals from the new facility augur well for the launch of a series of products in the USA during 2011"

For reasons of confidentiality, the Company is not in a position to disclose the name of the product.

About Agila Specialties

Agila Specialties Private Limited is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company's restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 7 world class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.

About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.
The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350- scientist strong global R&D Centre located in Bangalore.
Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

Strides

PR Consultancy

Mr. V.S. Iyer, CEO - Agila
+91 80 66580111
Mr. Kannan. N (Investors)
+91 98450 54745
Melissa Arulappan (Media)
+91 98450 22389
Corporate Voice | Weber Shandwick
Mahesh Nair,
+91 9880376648 [email protected]
Hiba Kunil
+91 98807 26372 [email protected]

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on STRIDES SHASUN LTD
05/19 STRIDES SHASUN : announces joint venture with Vivimed labs
05/19 STRIDES SHASUN : inks JV pact with Vivimed Labs
05/06 STRIDES SHASUN : announces successful completion of third consecutive US FDA ins..
05/06 STRIDES SHASUN : s plant completes successful USFDA inspection
05/06 STRIDES SHASUN : gains on clearing US FDA audit for its Puducherry API plant
05/02 STRIDES SHASUN : Stride Shasun receives 'zero' 483 observations, stock up
04/25 STRIDES SHASUN : gains 3% as Cuddalore facility clears USFDA inspection
03/26 STRIDES SHASUN : Quarterly results - strides shasun limited
03/26 STRIDES SHASUN : Trailing twelve month results - strides shasun limited
03/22 STRIDES SHASUN : Sequent demerger
More news
Sector news : Generic Pharmaceuticals
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Generic Pharmaceuticals
Advertisement
Financials ( INR)
Sales 2018 38 702 M
EBIT 2018 6 540 M
Net income 2018 4 268 M
Debt 2018 17 551 M
Yield 2018 0,65%
P/E ratio 2018 18,81
P/E ratio 2019 13,86
EV / Sales 2018 2,57x
EV / Sales 2019 2,25x
Capitalization 81 929 M
More Financials
Chart STRIDES SHASUN LTD
Duration : Period :
Strides Shasun Ltd Technical Analysis Chart | STAR | INE939A01011 | 4-Traders
Full-screen chart
Technical analysis trends STRIDES SHASUN LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 1 258  INR
Spread / Average Target 37%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Arun N. Kumar Executive Vice Chairman & Managing Director
Shashank Sinha Chief Executive Officer
Deepak Calian Vaidya Chairman
Badree Komandur CFO, Secretary, Chief Compliance Officer & EVP
Sunil Nadkarni Chief Technical Services Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
STRIDES SHASUN LTD-13.34%1 271
OTSUKA HOLDINGS CO LTD-0.77%25 309
SUN PHARMACEUTICAL IND..-10.03%21 132
ONO PHARMACEUTICAL CO...-8.34%12 404
SHANGHAI FOSUN PHARMAC..34.10%10 966
ASPEN PHARMACARE HOLDI..4.00%10 475
More Results